X

Trial Profile

VAXZEVRIA Intramuscular Injection Specific Use Result Study for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1222 (Primary)
Indications COVID 2019 infections; COVID-19 respiratory infection
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

11 Mar 2024 Status changed from recruiting to discontinued because last vaccination day was crossed on 30 Sep 2022 according to Japan VAXZEVRIA vaccination plan.
13 Oct 2022 Planned End Date changed from 30 Nov 2022 to 20 Apr 2029.
13 Oct 2022 Planned primary completion date changed from 30 Nov 2022 to 20 Apr 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com